Navigation Links
Reagan-Udall Foundation Announces New Board Chairman
Date:7/15/2014

WASHINGTON, July 15, 2014 /PRNewswire-USNewswire/ -- The Reagan-Udall Foundation for the FDA (RUF), an independent not-for-profit organization created by Congress for the purpose of advancing regulatory science critical to helping the U.S. Food and Drug Administration accomplish its mission, today announced that Mark C. Rogers, M.D., M.B.A., has been elected as Chairman of the RUF Board of Directors.

"It's an honor to welcome a physician, scientist, educator and executive as distinguished as Dr. Rogers to govern our Board," said Ellen V. Sigal, Ph.D., RUF Board Vice Chairman and Interim Board Chairman during the search. "Dr. Rogers brings with him decades of outstanding leadership in several fields of medicine and business. His experience and guidance will help to strengthen the Foundation's contribution to regulatory science."  Dr. Rogers succeeds Mark McClellan, M.D., Ph.D., the Board's founding Chairman, who continues to support the Foundation as a Board member leading the Innovation in Medical Evidence Development and Surveillance (IMEDS) program.

"It's a great privilege to be appointed Chair of this unique collaboration that has already contributed so much to advancing public health in just a few years," said Dr. Rogers. "I have great confidence that we'll continue to make important strides in accelerating regulatory science and ensuring FDA-regulated products that reach consumers continue to meet the highest standards of safety, efficacy and quality."

Following Dr. Rogers' appointment in 1977 as the first Director of the Pediatric Intensive Care Unit at The Johns Hopkins Hospital, he went on to be appointed Professor and Chair of the Department of Anesthesiology and Critical Care Medicine, then Associate Dean. He received his M.B.A. from the Wharton School of the University of Pennsylvania and, among other publications, authored what is now the international standard textbook in pediatric intensive care. Dr. Rogers has held several senior, pioneering leadership and foundational roles in biotechnology and biopharmaceutical companies and is involved in a number of public service activities.

The Reagan-Udall Foundation for the FDA is an independent 501(c)(3) not-for-profit organization created by Congress to advance the mission of the FDA by advancing regulatory science and research. With the ultimate goal of improving public health, the Foundation provides a unique opportunity to bring all parties to the table (FDA, patient groups, academia, other government entities and industry) to work together in a transparent way to create exciting new regulatory science.

 


'/>"/>
SOURCE Reagan-Udall Foundation for the FDA
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
2. Leaders in Science Join Upcoming Celebration of the 100th Anniversary of the Oldest Science Foundation in America
3. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
4. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
5. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
6. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
7. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
8. NeuroPhage Receives Michael J. Fox Foundation Funding for Parkinsons Disease Research
9. Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant
10. Foundation for Health Improvement and Technology (FHIT) Launched to Beat Cardiovascular Disease
11. Systems Alliance Launches Redesigned Website for The Living Legacy Foundation of Maryland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer and recently formed ... entered into a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. The ... gene editing across all applications. , Under the terms of the agreement, Pioneer ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its national ... Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based ... selected for membership in ARCS Alumni Hall of Fame . ASTER Labs ...
(Date:10/11/2017)... INDIANAPOLIS , Oct. 11, 2017  VMS BioMarketing, a ... of a nationwide oncology Clinical Nurse Educator (CNE) network, which ... growing need for communication among health care professionals to enhance ... physicians, nurses, office staff, and other health care professionals to ... for breast cancer. ...
(Date:10/10/2017)... ... ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled a ... new look is part of a transformation to increase awareness, appeal to new markets ... It will also expand its service offering from its signature gourmet cooking classes and ...
Breaking Biology Technology:
(Date:10/4/2017)... BLOOMINGTON, Ill. , Oct. 4, 2017  GCE Solutions, a ... powerful new data and document anonymization solution on October 4, 2017. ... the pharmaceutical field to comply with policy 0070 of the European ... documents and data. ... Innovation by GCE Solutions ...
(Date:8/15/2017)... Aug. 15 2017   ivWatch LLC , a medical device ... therapy, today announced receipt of its ISO 13485 Certification, the global ... International Organization for Standardization (ISO┬«). ... ivWatch Model 400 Continuous Monitoring device for the early detection of ... "This is an important milestone ...
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
Breaking Biology News(10 mins):